dc.creator | Romero Gómez, Manuel | es |
dc.creator | Kachru, N. | es |
dc.creator | Ascanio Zamorano, M. | es |
dc.creator | Darba, J. | es |
dc.creator | Shreay, S. | es |
dc.date.accessioned | 2023-07-18T07:33:59Z | |
dc.date.available | 2023-07-18T07:33:59Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Romero Gómez, M., Kachru, N., Ascanio Zamorano, M., Darba, J. y Shreay, S. (2020). Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine, 99 (50), e23506. https://doi.org/10.1097/MD.0000000000023506. | |
dc.identifier.issn | 0025-7974 | es |
dc.identifier.issn | 1536-5964 | es |
dc.identifier.uri | https://hdl.handle.net/11441/148031 | |
dc.description.abstract | The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) presents many public health challenges, including a substantial impact on healthcare resource utilization and costs. There are important regional differences in the burden of NAFLD/NASH, and Spain-specific data are lacking. This retrospective, observational study examined the impact of liver disease severity, comorbidities, and demographics on healthcare resource utilization and costs in Spain.NAFLD/NASH patients in the Spanish National Health System's Hospital Discharge Records Database (1/1/2006 to 4/30/2017) were categorized into disease severity cohorts as NAFLD/NASH overall, NAFLD/NASH non-progressors, compensated cirrhosis (CC), decompensated cirrhosis (DCC), liver transplant (LT), or hepatocellular carcinoma (HCC). Patients were followed from index date until the earliest of 6 months, disease progression, end of coverage, death, or end of study. Within each cohort, pre- and post-index healthcare resource utilization and costs per patient per month (PPPM) were calculated.A total of 8,205 patients (mean age 58.4; 54% male) were identified; 5,984 (72.9%) were non-progressors, 139 (1.7%) progressed to CC, 2,028 (24.7%) to DCC, 115 (1.4%) to LT, and 61 (0.7%) to HCC. Pre-index comorbidity burden was high across disease cohorts, and the frequency of comorbidities increased with disease severity. From pre- to post-index, average length of stay (LOS) increased significantly (23%-41%) as did all-cause PPPM costs (44%-46%), with significantly longer LOS and costs in patients with increasing disease severity.Progression of NAFLD/NASH was associated with significantly higher costs and longer LOS. A coordinated approach is needed to manage resources and costs in Spain. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 pág. | es |
dc.language.iso | eng | es |
dc.publisher | Lippincott, Williams & Wilkins | es |
dc.relation.ispartof | Medicine, 99 (50), e23506. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | NASH | es |
dc.subject | Advanced liver diseases | es |
dc.subject | Comorbidities | es |
dc.subject | Costs | es |
dc.subject | Length of stay | es |
dc.subject | NAFLD | es |
dc.title | Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://journals.lww.com/md-journal/Fulltext/2020/12110/Disease_severity_predicts_higher_healthcare_costs.72.aspx | es |
dc.identifier.doi | 10.1097/MD.0000000000023506 | es |
dc.journaltitle | Medicine | es |
dc.publication.volumen | 99 | es |
dc.publication.issue | 50 | es |
dc.publication.initialPage | e23506 | es |
dc.contributor.funder | Gilead Sciences, Inc. | es |